ArticlePediatrics open science
Opioid use disorder medications among youth in primary care: Subgroup analysis of the PROUD trial.
Article in Pediatrics open science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial.Addiction (Abingdon, England) · 2026Trial
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Objective: Medications for opioid use disorder (OUD) are under-utilized among adolescents and young adults ("youth"). Offering buprenorphine or naltrexone in primary care settings may reduce barriers to their use among youth. We conducted a secondary, patient-level analysis of the PROUD cluster-randomized clinical trial, which tested the implementation of a nurse care management intervention to support prescribing OUD medications. Methods: 12 primary care clinics from 6 health systems were randomized in 2018 and patient-level data was collected from 2 years before to 2 years after randomization. The primary outcome was any OUD medication treatment (i.e., buprenorphine or extended-release injectable naltrexone) during the post-randomization period for youth ages 16-25 years. Results: A total of 20,253 youth ages 16-25 years were seen in intervention and 26,562 in usual care clinics during the study period. Comparing patients by clinic arm, we did not detect a statistically significant difference in the odds of receiving OUD medication treatment after randomization (odds ratio 1.75, 95% CI 0.63-4.89). Among the small number of patients (n=67) who received OUD medication after randomization, median treatment days were 81.5 days (IQR 30-177) and 64 days (IQR 24-206) in intervention or usual care clinics, respectively. Conclusions: We did not find evidence that implementing a primary care nurse care management model meaningfully increased OUD medication treatment among youth. In this special population, youth-centered approaches may be needed to promote prescribing and overcome known barriers to care, such as provider and patient hesitancy to use OUD medications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.